The American Journal of Managed Care26 天
FDA Approves Revakinagene Taroretcel for Macular Telangiectasia Type 2
Revakinagene taroretcel-lwey is the first FDA-approved treatment for macular telangiectasia type 2, a progressive neurodegenerative retinal disease. The therapy uses an encapsulated cell-based ...
Healio27 天
FDA approves Encelto for macular telangiectasia type 2
Encelto is the first FDA-approved treatment for macular telangiectasia type 2. The cell therapy slows the loss of macular photoreceptors through continuous delivery of ciliary neurotrophic factor.
Business Wire26 天
Neurotech’s ENCELTO™ (revakinagene taroretcel-lwey) Approved by the FDA for the ...
About Macular Telangiectasia Type 2 (MacTel) Macular Telangiectasia Type 2 (MacTel), or idiopathic macular telangiectasia type 2, is a bilateral, neurodegenerative disease in adults with ...